Advertisement
U.S. markets closed
  • S&P 500

    5,088.80
    +1.77 (+0.03%)
     
  • Dow 30

    39,131.53
    +62.43 (+0.16%)
     
  • Nasdaq

    15,996.82
    -44.78 (-0.28%)
     
  • Russell 2000

    2,016.69
    +2.85 (+0.14%)
     
  • Crude Oil

    76.57
    +0.08 (+0.10%)
     
  • Gold

    2,045.80
    -3.60 (-0.18%)
     
  • Silver

    22.98
    -0.01 (-0.03%)
     
  • EUR/USD

    1.0820
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    4.2600
    -0.0670 (-1.55%)
     
  • GBP/USD

    1.2672
    +0.0014 (+0.11%)
     
  • USD/JPY

    150.4200
    -0.0800 (-0.05%)
     
  • Bitcoin USD

    51,709.84
    +204.21 (+0.40%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,706.28
    +21.79 (+0.28%)
     
  • Nikkei 225

    39,098.68
    +836.48 (+2.19%)
     

UPDATE 1-Moderna to file for EUA of COVID-19 shot for very young kids by April end

(adds details, background on Pfizer/BioNTech)

April 20 (Reuters) - Moderna plans to submit an application to the U.S. health regulator for emergency use authorization (EUA) of its COVID-19 vaccine among kids between the ages of six months to five years by end of the month, a company spokesperson said on Wednesday.

The Omicron variant was predominant during Moderna's pediatric trial, and the drugmaker said two doses were around 38% effective in preventing infections in 2 to 5-year-olds and 44% effective for children aged 6 months to under 2 years.

Last week, Pfizer Inc and BioNTech said a third dose of the COVID-19 vaccine produced significant protection against the Omicron variant in healthy children from ages 5 to 11.

Earlier this year, the U.S. Food & Drug Administration authorized a third dose of the Pfizer/BioNTech vaccine for children ages 12 to 15 and those aged 5 through 11 who are immunocompromised. (Reporting by Sabahatjahan Contractor and Amruta Khandekar; Editing by Krishna Chandra Eluri)

Advertisement